2015年10月15日

“善意的信念”没有诱导防御专利侵权芬兰公司LS CancerDiag有限公司(http://www.lscancerdiag.com/)自豪地宣布接受专利在澳大利亚DiagMMR™,继承的第一功能测试开发诊断错配修复(MMR)不足,即林奇综合症(LS)。此外,DiagMMR™全球专利申请等待10个市场领域。革命性的方法是基于20多年的学术研究在赫尔辛基大学测试开发一直由一个研究小组监督教授明娜Nystrom,领先的发明者DiagMMR™方法。林奇综合征的一个主要的单一原因肠癌和子宫内膜癌。高达1/370的人口估计携带MMR缺陷,数以百万计的人们可能在严重受到影响林奇综合症的风险。虽然目前的LS诊断依赖于肿瘤研究,定量DiagMMR™方法允许LS突变载体基于非侵入性诊断组织样本之前已经开发了一种癌症的人,和值得注意,没有知识和遗传致病突变的细节。“DNA修复机制的研究是至关重要的对我们理解林奇综合症的癌症发展。上周,2015年诺贝尔化学奖(http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2015/press.html)被授予三位研究者的映射,在分子水平,细胞如何修复受损DNA和保护基因信息”,Nystrom教授解释道。“我们很高兴能够利用这个开创性的研究和应用于预防卫生保健。“林奇综合症相关的癌症诊断市场价值350亿美元以7.5%的复合年增长率的预期。 Especially the volumes of predictive screening methods for detecting inherited cancer-causing conditions have been growing due to their nature of supporting preventive care as they can potentially reduce the overall health care costs significantly”, states Tuomas Poskiparta, Commercial Director of LS CancerDiag Ltd. “We are aiming at commercializing DiagMMR™ in 2017 and expect wide market adaptation, for it is the only functional test available to diagnose this complex syndrome with high cancer risk.” LS CancerDiag Ltd is a Finnish company committed to reducing cancer mortality rates with a low-cost, comprehensive diagnostic method that detects an inherited cancer-causing deficiency prior to cancer formation. DiagMMR™, developed by LS CancerDiag Ltd, is a functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome without prior knowledge of the individual’s genetic background. Established in 2013 and based in Helsinki, LS CancerDiag Ltd is targeting to commercialize DiagMMR™ in 2017. For more information, please visit http://www.lscancerdiag.com/ . This information was brought to you by Cision http://news.cision.com View source version on businesswire.com: http://www.businesswire.com/news/home/20151015005841/en/ For further information, please contact: Professor Minna Nyström Founder and Chairman